Literature DB >> 14979442

Efficacy of milbemycin oxime against fourth-stage larvae and adults of Ancylostoma tubaeforme in experimentally infected cats.

E Humbert-Droz1, G Büscher, D Cavalleri, P Junquera.   

Abstract

The efficacy of milbemycin oxime against fourth-stage (L4) larvae and adults of Ancylostoma tubaeforme was investigated in a trial involving 24 young domestic shorthair cats. The animals were inoculated with approximately 300 infective stage three (L3) larvae and divided into three groups. After 12 days, eight cats (group 1) were treated with medicated tablets containing 4 mg milbemycin and 10 mg praziquantel to test the efficacy against L4 larvae; eight cats in group 2 were treated with the same tablets after 33 days to test the efficacy against adult worms; and eight cats in group 3 were treated with a placebo tablet. Faecal egg counts were determined periodically in each cat and after 40 or 41 days the number of worms in each animal was determined postmortem. The egg count reduction was determined by comparing the geometric mean numbers of eggs per gram of faeces in the placebo and medicated groups, and the worm reduction by comparing the geometric mean numbers of worms. The egg count reduction was more than 99 per cent in both treated groups, while the number of worms in groups 1 and 2 were reduced by 94.7 per cent and 99.2 per cent, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14979442     DOI: 10.1136/vr.154.5.140

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  2 in total

Review 1.  Pet roundworms and hookworms: a continuing need for global worming.

Authors:  Donato Traversa
Journal:  Parasit Vectors       Date:  2012-05-10       Impact factor: 3.876

2.  Comparative palatability of two veterinary dewormers (Milpro(®) and Milbemax(®)): a blinded randomised crossover cat study.

Authors:  N Bernachon; D McGahie; D Corvaisier; E Benizeau; N Crastes; G Chaix
Journal:  Vet Rec Open       Date:  2014-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.